<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081480</url>
  </required_header>
  <id_info>
    <org_study_id>VALID2</org_study_id>
    <nct_id>NCT04081480</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Valacyclovir Oral Solution in Children</brief_title>
  <acronym>VALID2</acronym>
  <official_title>Pharmacokinetics of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) Infections in Children, Phase II (VALID II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Valacyclovir has replaced acyclovir in many clinical scenarios. Pharmacokinetic data support&#xD;
      the use of oral valacyclovir in children, but practical problems exist in children having to&#xD;
      take adult-dose tablets. A formulation with acceptable palatability, good pharmaceutical&#xD;
      quality and possibility of flexible dosing is developed. Pharmacokinetic data of this&#xD;
      formulation is missing.&#xD;
&#xD;
      The present study investigates the pharmacokinetics of valacyclovir oral solution in children&#xD;
      by determine the area under the curve (AUC0-12), time above critical concentration (Ccrit),&#xD;
      Cmax and Tmax of acyclovir.&#xD;
&#xD;
      Secondary, the safety profile of a single dose of valacyclovir oral solution will be&#xD;
      determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis showed positive results, it was difficult to include patients and also the&#xD;
    fact that the grant for this project has ended, we have decided to complete the study before we&#xD;
    had included the total number of 16 patients.&#xD;
  </why_stopped>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Actual">May 12, 2021</completion_date>
  <primary_completion_date type="Actual">May 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intervention is pharmacokinetic (PK) curve collection in children, two age groups</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>12 hours</time_frame>
    <description>Acyclovir area under the curve (12h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>12 hours</time_frame>
    <description>Maximum concentration of aciclovir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>12 hours</time_frame>
    <description>Time to reach maximum concentration of aciclovir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>1 day</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Herpes Simplex Virus Infection</condition>
  <condition>Varicella Zoster Virus Infection</condition>
  <arm_group>
    <arm_group_label>Valacyclovir oral solution</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Valacyclovir oral solution as administered in standard of care. Dosage: 10 mg/kg BID for children weighing less than 40 kg and 500 mg BID for children weighing 40 kg or more.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution</description>
    <arm_group_label>Valacyclovir oral solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is in the age of 2-12 years.&#xD;
&#xD;
          -  Subject has an indication for (val)acyclovir prophylaxis and are planned to receive&#xD;
             valacyclovir oral solution.&#xD;
&#xD;
          -  Subject is managed with a central venous catheter (CVC/Port-a-Cath).&#xD;
&#xD;
          -  Subject's parents have signed the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject is willing to participate after study procedures are explained in&#xD;
             comprehensible language for the child.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe anemia (&lt;6.0 mmol/L).&#xD;
&#xD;
          -  Full dose has not been taken.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prinses Maxima Centrum voor kinderoncologie</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Varicella Zoster Virus Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

